# US 2002/0058264 A1 · Human regulatory molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0058264 A1
- Document ID: US20020058264A1
- Status: Published application
- Kind: A1
- Application number: 09/840,787
- Filed: 2001-09-26
- Published: 2002-05-16
- Earliest claimed: 1997-09-23
- Assignees: Incyte Pharmaceuticals, Inc.
- Inventors: Preeti Lal; Jennifer L. Hillman; Olga Bandman; Purvi Shah; Janice Au-Young; Henry Yue; Karl J. Guegler; Neil C. Corley
- Web page: https://patentgrep.com/patent/US20020058264A1

## CPC

- C12N 9/93: {Ligases (6)}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- C07K 14/4702: {Regulators; Modulating activity}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y10T 436/143333: Saccharide [e.g., DNA, etc.]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The invention provides human regulatory molecules and the polynucleotides which identify and encode them. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention further provides methods for diagnosing and treating disorders associated with expression of human regulatory molecules.

## Claims

### Claim 1

A purified protein comprising an amino acid sequence selected from SEQ ID NOs: 1-49.

### Claim 2 (depends on 1)

An isolated polynucleotide comprising a nucleic acid sequence encoding the protein of claim 1 or the complement of the polynucleotide.

### Claim 3 (depends on 2)

A composition comprising a polynucleotide of claim 2 and a reporter molecule.

### Claim 4

An isolated polynucleotide comprising a nucleic acid sequence selected from SEQ ID NOs:50-98 and the complement of the polynucleotide.

### Claim 5 (depends on 2)

A vector containing the polynucleotide of claim 2.

### Claim 6 (depends on 5)

A host cell containing the vector of claim 5.

### Claim 7 (depends on 6)

A method for using a polynucleotide to produce a protein comprising:
a) culturing the host cell of claim 6 under conditions for the expression of the protein, and
b) recovering the protein from the host cell culture.

### Claim 8 (depends on 2)

A method for using a polynucleotide to detect expression of a nucleic acid in a sample, the method comprising:
a) hybridizing the polynucleotide of claim 2 to nucleic acids of the sample, thereby forming a hybridization complex, and
b) detecting hybridization complex formation, wherein complex formation indicates the expression of the polynucleotide in the sample.

### Claim 9 (depends on 8)

The method of claim 8 wherein the polynucleotide is attached to a substrate or bonded to the surface of a microarray.

### Claim 10 (depends on 8)

The method of claim 8 wherein the nucleic acids of the sample are amplified prior to hybridization.

### Claim 11 (depends on 2)

A method of using a polynucleotide to screen a plurality of molecules to identify a ligand, the method comprising:
a) combining the polynucleotide of claim 2 with a plurality of molecules under conditions to allow specific binding, and
b) detecting specific binding, thereby identifying a ligand which specifically binds the polynucleotide.

### Claim 12 (depends on 11)

The method of claim 11 wherein the molecules are selected from DNA molecules, RNA molecules, peptide nucleic acids, artificial chromosome constructions, peptides, and transcription factors.

### Claim 13 (depends on 2)

A method for diagnosing a disease associated with gene expression in a sample containing nucleic acids, the method comprising:
a) hybridizing a polynucleotide of claim 2 to nucleic acids of the sample under conditions to form a hybridization complex,
b) comparing hybridization complex formation with standards, thereby diagnosing the disease.

### Claim 14 (depends on 13)

The method of claim 13 wherein expression is diagnostic of cancer or immune response.

### Claim 15 (depends on 1)

A composition comprising the protein of claim 1 and a pharmaceutical carrier or a labeling moiety.

### Claim 16 (depends on 1)

A method for using a protein to screen a plurality of molecules to identify a ligand, the method comprising:
a) combining the protein of claim 1 with the molecules under conditions to allow specific binding, and
b) detecting specific binding, thereby identifying a ligand which specifically binds the protein.

### Claim 17 (depends on 16)

The method of claim 16 wherein the molecules are selected from DNA molecules, RNA molecules, peptide nucleic acids, peptides, pharmaceutical agents, proteins, mimetics, agonists, antagonists, Ned antibodies, immunoglobulins, inhibitors, and drugs.

### Claim 18 (depends on 1)

A method of using a protein to prepare and purify antibodies comprising:
a) immunizing a animal with the protein of claim 1 under conditions to elicit an antibody response,
b) isolating animal antibodies,
c) attaching the protein to a substrate,
d) contacting the substrate with isolated antibodies under conditions to allow specific binding to the protein,
e) dissociating the antibodies from the protein, thereby obtaining purified antibodies.

### Claim 19 (depends on 1)

An antibody which specifically binds a protein of claim 1.

### Claim 20 (depends on 19)

A method for using an antibody to detect protein expression in a sample, the method comprising:
a) combining the antibody of claim 19 with a sample under conditions to form antibody:protein complexes, and
b) detecting complex formation with standards, wherein detection indicates expression of the protein in the sample.
